BackAbbott Laboratories Overview
Abbott Laboratories

Abbott Laboratories Target Price

See Abbott Laboratories's analyst price targets ($120) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$108.8

Average Target Price

$122.8612.9% upside

7 analysts in the last 4 months

High: $134 | Low: $112

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-13Wolfe Research$13019.5% upsideOpen
2026-07-28UBSPatrick Wood$12514.9% upsideOpen
2026-07-20Benchmark Co.$12010.3% upsideOpen
2026-07-17Piper Sandler$1188.5% upsideOpen
2026-07-16BTIG$13423.2% upsideOpen
2026-07-06Evercore ISIVijay Kumar$1122.9% upsideOpen
2026-06-30Robert W. BairdDavid Rescott$12111.2% upsideOpen
2026-04-22Daiwa$9215.4% downsideOpen
2026-04-20BarclaysMatt Miksic$14331.4% upsideOpen
2026-04-17UBS$1155.7% upsideOpen
2026-04-17Piper Sandler$1155.7% upsideOpen
2026-04-17Stifel Nicolaus$12010.3% upsideOpen
2026-03-13UBSDanielle Antalffy$15845.2% upsideOpen
2026-03-13New Street$14533.3% upsideOpen
2026-02-02Barclays$14230.5% upsideOpen
2026-01-29Loop Capital MarketsIlya Zubkov$12010.3% upsideOpen
2026-01-23Evercore ISI$13826.8% upsideOpen
2026-01-23UBS$13221.3% upsideOpen
2026-01-23Mizuho SecuritiesAnthony Petrone$12514.9% upsideOpen
2026-01-23Piper Sandler$13524.1% upsideOpen
2026-01-23Bernstein$12514.9% upsideOpen
2026-01-23Wells FargoLarry Biegelsen$12212.1% upsideOpen
2026-01-09BernsteinLee Hambright$15441.5% upsideOpen
2026-01-09Goldman Sachs$15239.7% upsideOpen
2026-01-05Evercore ISI$14432.4% upsideOpen
2026-01-05Barclays$16955.3% upsideOpen
2025-12-22BTIGMarie Thibault$14533.3% upsideOpen
2025-11-21Tigress Financial$14533.3% upsideOpen
2025-10-17Barclays$16248.9% upsideOpen
2025-10-16Wells Fargo$14634.2% upsideOpen
2025-10-01Goldman Sachs$15744.3% upsideOpen
2025-07-15RBC CapitalShagun Singh$14735.1% upsideOpen
2025-04-15RBC CapitalShagun Singh$14028.7% upsideOpen
2025-01-08BernsteinLee Hambright$13524.1% upsideOpen
2024-10-17Piper SandlerAdam Maeder$13322.2% upsideOpen
2024-10-17BernsteinLee Hambright$13826.8% upsideOpen
2024-10-16JefferiesMatthew Taylor$12514.9% upsideOpen
2024-10-16Evercore ISIVijay Kumar$12817.6% upsideOpen
2024-10-16BTIGMarie Thibault$13927.8% upsideOpen
2024-10-08OppenheimerSuraj Kalia$13019.5% upsideOpen
2024-10-08SusquehannaCharles Minervino$12010.3% upsideOpen
2024-10-08RBC CapitalShagun Singh$13019.5% upsideOpen
2024-09-19Roth CapitalScott Fortune$24.0177.9% downsideOpen
2024-09-19RBC CapitalJonathan Atkin$165.6552.3% upsideOpen
2024-09-19Piper SandlerAdam Maeder$13120.4% upsideOpen
2024-08-27JefferiesMatthew Taylor$12010.3% upsideOpen
2024-08-22CitigroupJoanne Wuensch$12716.7% upsideOpen
2024-07-18CitigroupJoanna Wiensch$1199.4% upsideOpen
2024-07-18Raymond JamesJayson Bedford$12716.7% upsideOpen
2024-07-02Evercore ISIVijay Kumar$12010.3% upsideOpen

Abbott Laboratories (ABT) FAQ

Abbott Laboratories's target price stands at $120. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $120 for ABT implies 12.9% upside versus today's price ($108.8). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Abbott Laboratories's target price evolved across reporting periods, while the comparison chart places ABT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Abbott Laboratories's reading of $120 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.